^
    3d
    TAS-102 plus Fruquintinib or TAS-102 plus Fruquintinib in combination with Chidamide and Serplulimab as third-line and beyond treatment for metastatic colorectal cancer：A multicenter, randomized, two-arm clinical trial (ChiCTR2500115578)
    P4, N=64, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Fruzaqla (fruquintinib) • Epidaza (chidamide) • Lonsurf (trifluridine/tipiracil) • Hetronifly (serplulimab)
    3d
    Exploratory Clinical Study of Fruquintinib Combined with Sintilimab and Chemotherapy as Adjuvant Treatment for Stage III Gastric Cancer after Surgery (ChiCTR2500114651)
    P4, N=32, Not yet recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New P4 trial
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    3d
    Trifluridine-Tipiracil plus Fruquintinib vs Trifluridine-Tipiracil plus Bevacizumab for Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority trial (TAS-FUR) (ChiCTR2500112138)
    P4, N=236, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New P4 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    3d
    Sulfasalazine combined with fruquintinib and sintilimab‌ for ‌third-line or later treatment of advanced pMMR/MSS colorectal cancer: an open-label, single-arm, exploratory study. (ChiCTR2600116822)
    P2, N=37, Not yet recruiting, The First Afliated Hospital of Anhui Medical University; The First Afliated Hospital of Anhui Medical University
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    3d
    Iparomlimab and Tuvonralimab combined with fruquintinib in the treatment of dMMR/MSI-H colorectal cancer that has failed previous immune checkpoint inhibitor therapy: a single-center, single-arm, IIT trial (ChiCTR2500111438)
    P2, N=17, Not yet recruiting, Shanghai East Hospital; Shanghai East Hospital
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Prospective Study With HIPEC and AS regimen plus PD-L1 antibody with Fruquintinib in Patients With Peritoneal Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (ChiCTR2500113398)
    P2, N=52, Not yet recruiting, Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    albumin-bound paclitaxel • Fruzaqla (fruquintinib) • Teysuno (gimeracil/oteracil/tegafur)
    3d
    A phase II clinical trial of epalolitoporvorellimab (QL1706) in combination with fruquintinib for the treatment of immunocompetent pMMR/MSS metastatic colorectal cancer that has failed second- or higher lines of therapy. (ChiCTR2500112464)
    P2, N=18, Not yet recruiting, Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • ARID1A (AT-rich interaction domain 1A) • POLE (DNA Polymerase Epsilon) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • POLD1 (DNA Polymerase Delta 1)
    |
    ARID1A mutation
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab)
    3d
    Camrelizumab Combined with Fruquintinib and Sodium Propionate Capsules for Late-Line Treatment of Advanced Metastatic Colorectal Cancer in a Phase II Study (ChiCTR2500112349)
    P2, N=38, Not yet recruiting, The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    AiRuiKa (camrelizumab) • Fruzaqla (fruquintinib)
    6d
    SALVLIV: Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment (clinicaltrials.gov)
    P=N/A, N=47, Active, not recruiting, Peking University | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Jan 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib)
    7d
    A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=594, Recruiting, AskGene Pharma, Inc. | Phase classification: P1 --> P1/2 | N=104 --> 594 | Trial completion date: Dec 2025 --> Jun 2028 | Trial primary completion date: Mar 2024 --> Dec 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • paclitaxel • docetaxel • Fruzaqla (fruquintinib) • ASKG915
    11d
    Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) (clinicaltrials.gov)
    P3, N=224, Not yet recruiting, Fudan University
    New P3 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • Fruzaqla (fruquintinib)
    12d
    A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study (clinicaltrials.gov)
    P2, N=50, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Feb 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF mutation • RAS wild-type
    |
    Fruzaqla (fruquintinib) • Hetronifly (serplulimab)